Claude Chahine

Dynamic Assistant Professor with over a decade of experience in advancing hematology and oncology curriculum development and delivery. Committed to enhancing program outcomes through active engagement and support of learning objectives, fostering an enriching educational environment. Passionate educator with a strong foundation in academic advisement, dedicated to empowering students and promoting their success. Proven ability to inspire and motivate learners while driving innovative teaching strategies.

• Supervised team of 10 staff members.

• Membre du Groupe LYSA LYMPHOMA
• Membre de la SFGMT

• Licensed hematologist and oncologist -13 years

• Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical? Micol JB, Chahine C, Woerther PL, Ghez D, Netzer F, Dufour C, Merad M, Blot F, Chachaty E, de Botton S, Gachot B. Clin Microbiol Infect. 2014 Jul;20(7):0453-5
• Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease. Annereau M, Willekens C, El Halabi L, Chahine C, Saada V, Auger N, Danu A, Bermudez E, Lazarovici J, Ghez D, Leary A, Pistilli B, Lemare F, Solary E, de Botton S, Desmaris RP, Micol JB. Leuk Res. April 2017 ; 55 :58-64
• 12 years, disease-free survival after major hepatectomy and sub-total gastrectomy for gastric adenocarcinoma with synchronous multiple liver metastasis Lionel El Khoury; Claude Chahine; Elias Chahine; Elias Saikaly; Antonio D’alessandro; Elie Chouillard, International Journal of Scientific Research VI October 2017
• Haematological immune –related adverse event induced by anti-PD-1 or anti-PD-L1 immunotherapy: A descriptive observational study Nicolas Delanoy , Jean-Marie Michot, Thibault Comont , Nora Kramkimel, Julien Lazarovici , Romain Dupont , Stéphane Champiat , Claude Chahine , Caroline Robert , Charles Herbaux , Benjamin Besse , Aude Guillemin , Christine Mateus , Patricia Pautier , Philippe Saïag , Emanuela Madonna , Marie Maerevoet , Jean-Christophe Bout , Charlotte Leduc , Pascal Biscay , Gilles Quere , Charlée Nardin , Mikael Ebbo , Laurence Albiges , Grégoire Marret , Virginie Levrat , Cécile Dujon , Jacques Varafajtic , Salim Laghouati , Laure Croisille, Anne-Laure Voisin , Bertrand Godeau , Christophe Massard , Vincent Ribrag , Aurélien Marabelle , Marc Michel, Olivier Lambotte. Lancet Haematol. 2019 Jan;6(1):e48-e57
• High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell Non-Hodgkin’s Lymphoma, a phase II result Michot JM, Annereau M, Danu A, Legoupli C, Bertin L, Chahine C, Achab N, Antoisovka A, Cerutti A, Rossignol J, Ghez D, Willekens C, Dartigues P, Lazarovici J, Lemare F, Ribrag V. Eur J Haematol. 2020 Apr;104(4):281-290
• Repeated courses of low dose 2 X 2 Gy radiation therapy in patients with indolent B-Cell non-Hodgkin Lymphomas Khalil Saleh, Jean-Marie Michot , Antoine Schernberg , Julien Lazarovici , Claude Chahine , Alina Danu , Nadine Khalife-Saleh , Julien Rossignol , David Ghez , Valentine Martin , Renaud Mazeron , Christophe Fermé , Angela Boros , Vincent Ribrag , Theodore Girinsky . Cancer Med. 2020 Jun;9(11):3725-3732
• Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation Florence Pasquier, Claude Chahine, Christophe Marzac &Stéphane de Botton Expert Review of Precision Medicine and Drug Development (2020)
• Bortezomib, Lenalidomide, and dexamethasone in elderly patients with Blastic plasmacytoid dendritic cell neoplasm Claude Chahine, Damien Roos-Weil, Véronique Saada, Stéphane de Botton, Jean-Baptiste Micol , Stéphane Barete , Christophe Marzac , David Ghez . Clin Lymphoma Myeloma Leuk. 2020 Aug 5:S2152-2650(20)30380-3
• Chemotherapy-free regimen: a new hope in Philadelphia-positive acute lymphoblastic leukemia. Saleh K, Chahine C, Khalife N Future Oncol. 2021 Apr;17(11):1265-1267
• Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma. Michot JM, Buet-Elfassy A, Annereau M, Lazarovici J, Danu A, Sarkozy C, Chahine C, Bigenwald C, Bosq J, Rossignol J, Romano-Martin P, Baldini C, Ghez D, Dartigues P, Massard C, Ribrag V. Cancer Drug Resist. 2021 Mar 26;4(3):710-718
• Urothelial carcinoma in the era of immune checkpoint inhibitors. Khalife N, Chahine C, Kordahi M, Felefly T, Kourie HR, Saleh K. Immunotherapy. 2021 Aug;13(11):953-964
• The CLIP1-LTK fusion: a new oncogenic driver in non-small-cell lung cancer? Ibrahim R, Chahine C, Felefly T, Khalife N, Saleh K. Future Oncol. 2023 Feb;19(4):273-275
• Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma. Khoury R, Chahine C, Ibrahim R, Khalife N, Saleh M, Saleh K Future Oncol. 2023 Jun;19(17):1161-1163
• Mechanisms of Resistance to Antibody-Drug Conjugates. Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, Lecesne A. Int J Mol Sci. 2023 Jun 2;24(11):9674.
• LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy. Ibrahim R, Saleh K, Chahine C, Khoury R, Khalife N, Cesne AL. Biomedicines. 2023 Jul 1;11(7):1878
• When monoclonal gammopathy-associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes. Willekens C, Chahine C, Dragani M, Khalife-Hachem S, Bigenwald C, Rossignol J, Castilla-Llorente C, Danu A, Michot JM, Saada V, Cotteret S, Marzac C, Renneville A, Plo I, Broutin S, Bosselut N, Cassinat B, Lazarovici J, Droin N, De Botton S. EJHaem. 2023 May 19;4(3):823-826
• KRASG12C mutation in metastatic colorectal cancer: a new target. Ibrahim R, Saleh K, Chahine C, Khoury R, Khalife N, Lecesne A. Future Oncol. 2023 Aug;19(24):1641-1643.